Nothing Special   »   [go: up one dir, main page]

Buecklein et al., 2018 - Google Patents

Flow cytometric assessment of minimal residual disease in AML: National harmonization in the HARMONIZE initiative

Buecklein et al., 2018

Document ID
17979812083391131316
Author
Buecklein V
Schnorfeil F
Koehnke T
Spiekermann K
Krause S
Oelschlägel U
Völkl S
Rieger M
Berg T
Hoffmann J
Brendel C
Hofmeister-Mielke N
Kriegsmann K
Thiede C
von Bonin M
Subklewe M
Publication year
Publication venue
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie

External Links

Snippet

Methods: In a retrospective analysis of pilot data from one center (Munich), bone marrow samples from AML patients after intensive induction chemotherapy were assessed by multicolor flow cytometry at aplasia and post induction. The Kaplan-Meier estimator and log …
Continue reading at karger.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/569Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases

Similar Documents

Publication Publication Date Title
US11932696B2 (en) Method of treating cancer with an anti-CCR8 that binds tumor infiltrating cells
CN106068276B (en) Chimeric Antigen Receptor (CAR) with antigen binding domain to T cell receptor beta constant region
US20220152176A1 (en) Cancer biomarkers for durable clinical benefit
KR20190026740A (en) Treatment of B-cell malignancies using adoptive cell therapy
Zeng et al. Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia
JP2021503952A (en) CAR-T cells targeting IL-1RAP and their use
JP2021503952A5 (en)
Hanvesakul et al. KIR and HLA-C interactions promote differential dendritic cell maturation and is a major determinant of graft failure following kidney transplantation
Zhang et al. Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
Somasundaram et al. Systemic immune dysfunction in cancer patients driven by IL6 induction of LAG3 in peripheral CD8+ T cells
Buecklein et al. Flow cytometric assessment of minimal residual disease in AML: National harmonization in the HARMONIZE initiative
Won et al. A new triggering receptor expressed on myeloid cells (TREM) family member, TLT-6, is involved in activation and proliferation of macrophages
CA3218590A1 (en) Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
Trefny Resistance Mechanisms in Cancer Immunotherapy
Dwivedi Effect of claudin-6 and claudin-9 on NK cell cytotoxic activity against AGS cell line= Efecto de claudina-6 y claudina-9 sobre la actividad citotóxica de células NK contra la línea celular AGS
Parisi Immune response against Wilms Tumor: characterization of cellular and molecular interactions and identification of novel therapeutic targets
Ellert-Miklaszewska et al. 7aaRGD-a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas
Collins Enhanced Co-Stimulatory Signaling Improves Car T Cell Effector Responses In Chronic Lymphocytic Leukemia
Harte Chemokine and inhibitory receptor expression influences T cell migration and function in colorectal cancer patients
Kramářová Deep profiling of immune regulatory networks in the bone marrow of patients with diverse acute myeloid leukemia subtypes
Tarhoni Characterization of Biomarkers Associated with Response to Programmed Cell Death Protein-1/Programmed Cell Death Ligand-1 Inhibition in Patients with Advanced Stage Non-small Cell Lung Cancer
Spiliopoulou et al. Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers
Palakurthi Maximizing the Anti-tumor Potential of Immune Checkpoint Blockade through Modulation of Myeloid-specific CXCL16 and STAT1 Signaling
Aziz et al. Study of immunomics and immune regulation in ovarian cancer
dos Santos The role of hypoxia on immunomodulation at the colon cancer microenvironment